期刊文献+

局部晚期宫颈癌患者综合治疗的可行性分析 被引量:11

Feasibility analysis of comprehensive treatment on locally advanced cervical carcinoma
下载PDF
导出
摘要 目的探讨术前腔内后装放疗+化疗结合宫颈癌根治术及术后同步放化疗治疗局部晚期宫颈癌方案的可行性。方法研究组36例局部晚期宫颈癌患者腔内后装放疗2~3次加同期动脉介入或静脉化疗一程,休息后行宫颈癌根治术,术后同步放化疗,定期随诊;对照组32例局部晚期宫颈癌患者行根治性放疗加同期化疗(同步放化疗),观察两组的疗效和毒副反应,并进行对照分析。结果在肿瘤盆腔局部控制方面研究组优于对照组(P<0.05),而在肿瘤远处转移及生存方面两组间的差异无统计学意义(P>0.05);研究组患者治疗前后血清鳞状细胞癌相关抗原(SCCAg)值的下降较对照组显著,差异有统计学意义(P<0.001);两组未绝经患者治疗后出现更年期症状的差异有统计学意义(P<0.001);两组毒副反应的差异无统计学意义(P>0.05)。结论术前腔内后装放疗+化疗结合宫颈癌根治术及术后同步放化疗的治疗方案是治疗局部晚期宫颈癌的有效策略。 Objective To explore the feasibility of applying the comprehensive treatment including preoperative intracavitary brachytherapy plus chemotherapy, radical surgery of cervical carcinoma, and postoperative concurrent chemo-radiotherapy for locally advanced cervical carcinoma. Methods A total of sixty- eight patients with locally advanced cervical carcinoma were recruited and divided into study group (n = 36) and control group (n = 32). Patients in study group were given 2-3 courses of intracavitary brachytherapy and 1 course of arterial interventional or intravenous chemotherapy. After a short period of rest, the patients received radical surgery of cervical carcinoma. Postoperative concurrent chemo-radiotherapy and regular follow-ups were carried out afterwards. Patients in control group received radical radiotherapy plus concomitant chemotherapy (concurrent chemo-radiotherapy). The effects and toxicity of the treatment were observed, and evaluation indexes were compared between the two groups. Results Patients in study group demonstrated a significantly better control of local pelvic tumor size compared with their counterparts in control group (P〈 0.05). However, no significant differences were found in distant tumor metastasis and survival rate between the two groups (P 〉 0.05). The patients in study group showed a significantly sharper decrease in serum SCCAg value compared to those in control group (P〈O. 001). There was a significant difference in the incidence rate of post-treatment menopausal symptoms among the premenopausal patients in study group and control group (P〈 O. 001). The two groups did not differ significantly in toxicity (P〉0.05). Conclusion It is feasible and effective to apply thecomprehensive treatment including preoperative intracavitary brachytherapy plus chemotherapy, radical surgery of cervical carcinoma, and postoperative concurrent chemo-radiotherapy for locally advanced cervical carcinoma.
出处 《西安交通大学学报(医学版)》 CAS CSCD 北大核心 2013年第3期375-378,共4页 Journal of Xi’an Jiaotong University(Medical Sciences)
基金 陕西省自然科学基础研究基金资助项目(No.2012JM4006)~~
关键词 局部晚期宫颈癌 综合治疗 鳞状细胞癌相关抗原 locally advanced cervical carcinoma comprehensive treatment ACCAg
  • 相关文献

参考文献6

  • 1SEDLIS A, BUNDY BN, ROTMAN MI, et al. A randomized trial of pelvic radiation therapy versus no further therapy in se- lected patients with stage I B carcinoma of the pervix after radi- cal hysterectomy and pelvic lymphadenectomy: A gynecologic ontology group study [J]. Gynecol Oncol, 1999, 73 : 177-183.
  • 2ROSE PG, BUNDY BN, WATKINS EB, et al. Concurrent cis- platin-based radiotherapy and chemotherapy for locally advanced cervical cancer [J]. New Eng JMed, 1999, 340:1144-1153.
  • 3PETER WA, LIU PY, BARRETT RJ, et al. Concurrent chem- otherapy and pelvic radiation therapy compared with pelvic radi- ation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix [J]. J Clin Oncol, 2000, 18:1606-1613.
  • 4K1M HS, PARK NH, WU HG, et al. Matched-case comparison for the role of surgery in FIGO stage I bl - II a squamous cell carcinoma of cervix and suspicious para-aortic lymph node me- tastasis I-J]. Ann Surg Oncol, 2009, 16 (1):133-139.
  • 5EIFEL PJ. Concurrent chemotherapy and radiation therapy as the standard of care for cervical cancer [J]. Nat Clin Pract On- col, 2006, 3(5) :248-255.
  • 6魏毓蕾,陈红晓,于海丽,曲芃芃.术前新辅助化疗加消瘤放疗用于局部晚期宫颈癌的临床分析[J].现代妇产科进展,2012,21(4):286-289. 被引量:16

二级参考文献13

  • 1Cho YH,Kim DY,Kim JH,et al.Comparative study ofneoadjuvant chemotherapy before radical hysterectomyand radical surgery alone in stageⅠB2-ⅡA bulky cervi-cal cancer[J].Gynecol Oncol,2009,20(1):22-27.
  • 2Zalewski K,Doniec J,Baranowski W,et al.Revised FIGOstaging systems for gynecologic malignancies-2009 update[J].Ginekol Pol,2010,81(10):778-782.
  • 3Suh DH,Kim YT,Wang KL,et al.Asian society of gyne-cologic oncology workshop 2010[J].Gynecol Oncol,2010,21(3):137-150.
  • 4Ferlay J,Shin HR,Bray F,et al.Estimates of worldwideburden of cancer in 2008:GLOBOCAN 2008[J].Int JCancer,2010,127(12):2893-2917.
  • 5Wang N,Guan QL,Wang K,et al.Radiochemotherapyversus radiotherapy in locally advanced cervical cancer:ameta-analysis[J].Arch Gynecol Obstet,2011,283(1):103-108.
  • 6Bocci A,Sismondi P,Sinistrero G,et al.Radiosurgical tre-atment of uterine cervix carcinoma at the 1st Clinic of Ob-stetrics and Gynecology of the University of Turin,(in theperiod 1972-1978)[J].Eur J Gynaecol Oncol,1981,2(1):9-16.
  • 7Napolitano U,Imperato F,Mossa B,et al.The role of neo-adjuvant chemotherapy for squamous cell cervical cancer(Ⅰb-Ⅲb):a long-term randomized trial[J].Eur J Gynaecol Oncol,2003,24(1):51-59.
  • 8Kim HS,Park NH,Wu HG et al.Matched-case compari-son for the role of surgery in FIGO stageⅠb1-Ⅱa squa-mous cell carcinoma of cervix and suspicious para-aorticlymph node metastasis[J].Ann Surg Oncol,2009,16(1):133-139.
  • 9Nawata S,Sueoka K,Fukushima C,et al.Biological func-tion and clinical significance of a serological tumormarker,squamous cell carcinoma antigen in squamouscell carcinoma of the uterine cervix[J].Tumor Biology,2008,29(1):21-24.
  • 10Eifel PJ.Concurrent chemotherapy and radiation therapyas the standard of care for cervical cancer[J].Nat ClinPract Oncol,2006,3(5):248-255.

共引文献15

同被引文献74

  • 1薛琴琴,张菊,俞青苗,金雯,杨梅,刘宁侠,高艳娥.宫颈癌组织表皮生长因子受体对TKI敏感性相关的基因突变研究[J].西安交通大学学报(医学版),2012,33(5):583-586. 被引量:5
  • 2王利娟,田园,高积勇.宫颈癌预后与表皮生长因子受体蛋白表达关系[J].中国妇幼健康研究,2006,17(4):280-282. 被引量:6
  • 3吴仁瑞,吴少雄,赵充,谢方云,高剑铭,胡伟汉,高远红,李凤岩,崔甜甜,卢泰祥.h-R3联合放疗治疗局部晚期鼻咽癌的Ⅱ期临床研究[J].癌症,2007,26(8):874-879. 被引量:24
  • 4陈慧君,吴绪峰,梁川,李晓兰.新辅助化疗在局部晚期宫颈癌中的疗效观察[J].中国肿瘤临床,2007,34(4):226-229. 被引量:36
  • 5Kim SJ,Rabbani ZN,Dong F. Phosphorylated epider-mal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer[J].{H}MEDICAL ONCOLOGY,2010,(1):91.
  • 6Ettinger DS. Clinical implications of EGFR expression in the development and progression of solid tumors:focus on non-small cell lung cancer[J].{H}Oncologist(the)t,2006,(4):358.
  • 7Harari PM. Epidermal growth factor receptor inhibition strat-egies in oncology[J].{H}Endocrine Related Cancer,2004,(4):689.
  • 8Koshiyama M,Kinezaki M,Uchida T. Chemosensitivi-ty testing of a novel platinum analog,nedaplatin (254-S),in human gynecological carcinomas:a comparison with cis-platin[J].{H}Anticancer Research,2005,(6C):4499.
  • 9Desoize B,Madoulet C. Particular aspects of platinum com-pounds used at present in cancer treatment[J].{H}Critical Reviews in Oncology/Hematology,2002,(3):317.
  • 10Bowers G,Reardon D,Hewitt T. The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal trans-duction responses of human carcinoma cells[J].Onco-gene,2001,(11):1388.

引证文献11

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部